Hymush en es it fr

Hymush Brand names, Hymush Analogs

Hymush Brand Names Mixture

  • No information avaliable

Hymush Chemical_Formula


Hymush RX_link


Hymush fda sheet

Hymush msds (material safety sheet)

Hymush Synthesis Reference

No information avaliable

Hymush Molecular Weight

192.258 g/mol

Hymush Melting Point

246-266 oC

Hymush H2O Solubility

1.07E+004 mg/L

Hymush State


Hymush LogP


Hymush Dosage Forms

400 mg and 600 mg tablets for oral administration

Hymush Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Hymush Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Hymush Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Hymush side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Hymush Patient Information

Hymush Organisms Affected

Humans and other mammals